Patient stem cells grown into sickling red blood cells offer a new sickle cell disease model
Researchers reprogrammed blood cells from sickle cell patients into iPSCs and generated enucleated red cells that sickle under low oxygen, while developing a xeno-free erythroid differentiation formulation.
Summary
Stem-cell-derived red blood cells often remain immature, limiting their use in sickle cell disease research. This study developed a three-stage erythroid differentiation protocol using iPSCs reprogrammed from blood cells of healthy donors and patients with homozygous sickle cell disease. The resulting cells included enucleated, β-globin-expressing red cells with adult hemoglobin tetramers; patient-derived cells sickled under low oxygen. RNA sequencing identified disease-relevant pathway dysregulation. Replacing bovine serum albumin with polyvinyl alcohol increased cell production without loss of terminal maturation. The xeno-free erythroid formulation offers a patient-specific laboratory model, not a treatment or a demonstrated animal-free workflow from start to finish.
Detailed Summary
Sickle cell disease (SCD) is caused by a mutation in the β-globin gene, but patients differ in disease severity and treatment response. Patient-specific laboratory models could help investigate this variation. Existing iPSC-based red-cell protocols often produce immature cells with limited β-globin expression and poor enucleation.
The researchers generated induced pluripotent stem cells (iPSCs) from peripheral blood mononuclear cells of unrelated healthy donors and patients with homozygous SCD (HbSS). They used a commercial hematopoietic differentiation kit to produce CD34+ progenitors. The supplied methods report similar progenitor yields and comparable immunophenotypic profiles across genotypes.
The erythroid differentiation phase comprised three stages over 18 days. The original medium included human plasma and bovine serum albumin. In the modified formulation, bovine serum albumin was replaced with 0.8% w/v polyvinyl alcohol (PVA), while human plasma and other components were retained. The methods describe at least six independent experiments and measurements using flow cytometry, RT-qPCR, HPLC, microscopy, electron microscopy and RNA sequencing. They also describe hypoxic conditioning at 5% oxygen for 24 or 48 hours and a phalloidin permeability assay.
According to the abstract, the protocol generated enucleated, β-globin-expressing induced red blood cells with a GlyA+Band3+CD71lo phenotype and adult hemoglobin tetramers. SCD-derived cells displayed sickling under hypoxia. RNA sequencing of SCD reticulocytes identified dysregulated disease-relevant molecular pathways. The abstract further reports that the PVA formulation significantly increased cell production without loss of terminal maturation.
These findings support a patient-specific in vitro platform for studying SCD and developing potential therapies, not a treatment ready for patients. The supplied text ends during the methods and does not provide detailed outcome data, effect sizes or p-values. It therefore cannot substantiate exact enucleation or sickling rates, hemoglobin proportions, plasma-versus-serum comparisons or specific pathway-level results. The xeno-free claim concerns the erythroid differentiation formulation; earlier iPSC maintenance and hemogenic differentiation used Matrigel-coated plates.
Key Findings
- A three-stage, 18-day erythroid differentiation protocol generated enucleated, β-globin-expressing red cells from healthy-donor and homozygous SCD patient-derived iPSCs.
- The induced red cells had a GlyA+Band3+CD71lo phenotype and expressed adult hemoglobin tetramers.
- SCD-derived red cells displayed sickling under hypoxia; the supplied text does not give a sickling percentage.
- RNA sequencing of SCD reticulocytes identified dysregulated disease-relevant pathways, without detailed pathway results in the supplied text.
- Replacing bovine serum albumin with 0.8% w/v PVA significantly increased induced red-cell production without loss of terminal maturation.
- The xeno-free erythroid formulation retained human plasma; earlier stages of the workflow used Matrigel-coated plates.
Methodology
iPSCs were generated from peripheral blood mononuclear cells of unrelated healthy donors and patients with homozygous SCD; the methods also identify CRISPR-repaired lines. A commercial hematopoietic differentiation kit and CD34 enrichment preceded an 18-day, three-stage erythroid differentiation protocol. Cultures were maintained under normoxia, with 24- or 48-hour conditioning at 5% oxygen in some experiments. The modified medium replaced bovine serum albumin with 0.8% w/v PVA while retaining 5% human plasma. Documented measurements included flow cytometry, RT-qPCR, HPLC, light and electron microscopy, and a phalloidin permeability assay. RNA-seq sampled iPSC-derived cells and peripheral-blood CD34+-derived cultured red cells in triplicate on days 11 and 15, using DESeq2, GO and GSEA for analysis. The methods state that results represent cumulative data from at least six independent experiments. The supplied text ends during the phalloidin assay methods.
Study Limitations
The work is in vitro and does not establish patient benefit or reproduce whole-body SCD effects. The supplied text includes the abstract, introduction and partial methods, ending during the phalloidin permeability assay. Detailed results are unavailable, preventing verification of outcome percentages, hemoglobin proportions, specific dysregulated pathways and statistical comparisons. The xeno-free erythroid formulation should not be equated with an entirely animal-free workflow because earlier stages used Matrigel-coated plates. Conflict-of-interest details are not included in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
